
Lori Youmshajekian
Science Journalist at Freelance
Freelance science journalist | #SHERP41 @NYU_journalism | words: @sciam @newscientist @abcnews @RetractionWatch @YaleE360 @Medscape and more
Articles
-
1 week ago |
technewstube.com | Lori Youmshajekian
Tech News Tube is a real time news feed of the latest technology news headlines.Follow all of the top tech sites in one place, on the web or your mobile device.
-
1 week ago |
wired.com | Lori Youmshajekian
Statistically, men are more likely than women to be diagnosed with type 2 diabetes, with about 18 million more men living with the condition worldwide. This doesn’t tell the whole story. When women do get a diagnosis, they’re often older and have a higher body fat mass. They’re also more likely to die from diabetes-related causes, especially heart disease. And some researchers think underdiagnosis might explain part of the gap—perhaps more cases are being missed in women.
-
3 weeks ago |
retractionwatch.com | Lori Youmshajekian
Since March of last year, Elsevier has pulled around 60 papers connected to companies in the Caucasus region that don’t seem to exist. The retraction notices attribute the decision to suspicious changes in authorship and the authors being unable to verify the existence of their employers. Online sleuths have also flagged potentially manipulated citations among the articles. Each of the retracted papers appears to follow an identical pattern, based on the details given in the retraction notices.
-
4 weeks ago |
livescience.com | Lori Youmshajekian
For most of her life, Alyssa Fraser took comfort in cooking. Fraser, a former food reporter from Minnesota, used to relish the process of whipping up her favorite chicken and vegetable recipe or batches of pasta. But after she started taking the popular weight-loss medication Wegovy, her culinary interests seemed to disappear because she became disinterested in food — and certain types of food became particularly off-putting.
-
1 month ago |
eoswetenschap.eu | Lori Youmshajekian
Afvalmedicijnen zoals Ozempic zijn ontwikkeld als levenslange behandelingen. Een nieuwe studie heeft in kaart gebracht dat de meeste mensen het medicijn na twee jaar niet meer gebruiken. Welke impact heeft dat? Medicijnen die gewichtsverlies bevorderen, zoals semaglutide – bekend onder de merknamen Wegovy en Ozempic – zijn razend populair geworden voor de behandeling van obesitas. Ze zijn vooral effectief als mensen ze eeuwig blijven innemen. Dat is iets dat in de praktijk niet gebeurt.
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →X (formerly Twitter)
- Followers
- 450
- Tweets
- 142
- DMs Open
- Yes

RT @evn_report: Armenia’s conservation success story has led to an unexpected challenge: a growing human-bear conflict. As rangers work to…

RT @CivilNetTV: Women’s representation in the upper levels of Armenia’s government has improved significantly in recent years, going from 1…

RT @WIRED: Women suffer from migraines three times as often as men, and often with more intensity. New research into the role of hormones i…